Carosi G, Quiros-Roldan E, Torti C, Antinori A, Bevilacqua M, Bonadonna R C, Bonfanti P, Castagna A, Cauda R, d'Arminio-Monforte A, Di Gregorio P, Di Perri G, Esposito R, Fatuzzo F, Gervasoni C, Giannattasio C, Guaraldi G, Lazzarin A, Lo Caputo S, Maggi P, Mazzotta F, Moroni M, Prestileo T, Ranieri R, Rizzardini G, Russo R, Galli M
Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia, P.le Spedali Civili, 1, 25123, Brescia, Italy.
Infection. 2007 Jun;35(3):134-42. doi: 10.1007/s15010-007-6295-5.
The present document contains recommendations for assessment, prevention and treatment of cardiovascular risk for HIV-infected patients. All recommendations were graded according to the strength and quality of the evidence and were voted on by 73 members of the Italian Cardiovascular Risk Guidelines Working Group which includes both experts in HIV/AIDS care and in cardiovascular and metabolic medicine. Since antiretroviral drug exposure represents only one risk factor, continued emphasis on an integrated management is given. This should include prevention and treatment of known cardiovascular risk factors (such as dyslipidaemia, diabetes, insulin resistance, healthy diet, physical activity, avoidance of smoking), but also rational switch of antiretroviral drugs. A rational switch strategy should consider both metabolic and anthropometric disturbances and effectiveness of antiretroviral regimens.
本文件包含针对HIV感染患者心血管风险评估、预防和治疗的建议。所有建议均根据证据的强度和质量进行分级，并由意大利心血管风险指南工作组的73名成员投票表决，该工作组包括HIV/AIDS护理专家以及心血管和代谢医学专家。由于抗逆转录病毒药物暴露只是一个风险因素，因此持续强调综合管理。这应包括已知心血管风险因素的预防和治疗（如血脂异常、糖尿病、胰岛素抵抗、健康饮食、体育活动、戒烟），还包括抗逆转录病毒药物的合理换药。合理的换药策略应考虑代谢和人体测量方面的紊乱以及抗逆转录病毒治疗方案的有效性。
